Clonality in the Myelodysplastic Syndromes
- 65 Downloads
The myelodysplastic syndromes (MDSs) comprise a heterogeneous group of stem cell disorders involving cytopenia and dysplastic changes in 3 hematopoietic lineages. Although it is accepted that MDS is a clonal disorder, the exact nature of the involvement of multipotent stem cells and progenitor cells has not been resolved. Most clonality studies of MDS support the proposal that the primary neoplastic event occurs, in most patients, at the level of a committed myeloid progenitor cell, capable of differentiation into multiple myeloid lineages. The extent of the involvement of T and B lymphocytes in MDS remains controversial. Much of the variation reported may result from disease heterogeneity and technical issues such as skewed methylation patterns occurring in studies analyzing X-chromosome inactivation patterns (XCIP) and possible impurities in lymphocyte preparation. A great deal of the evidence in support of T-lymphocyte involvement in MDS has been generated by XCIP studies, and some of these data need to be treated with caution, especially data from studies in which appropriate controls were omitted. In contrast, B-lymphocyte involvement in some patients with MDS is based on studies using more robust technology including combined immunophenotyping and fluorescence in situ hybridization. Clonality studies involving myeloid and lymphoid cells in MDS have yielded discrepant results with regard to the potential involvement of multipotent (lympho-myeloid) hematopoietic stem cells (HSCs). However, failure to detect a clonal marker in all cells of all lineages does not preclude multipotent-HSC involvement. Some recent studies have produced compelling evidence to show that, in some patients with MDS, the multipotent HSC is the target of the primary neoplastic event. It now seems probable that MDS arises in multipotent HSCs more commonly than previously recognized. Such data not only provide important new insights into the biology of MDS but also may have therapeutic implications. The determination of whether multipotent HSCs are involved in the MDS clone may be important for the use of autologous stem cell transplantation in these patients.
Key wordsMyelodysplastic syndromes Multipotent hematopoietic stem cell Clonality X-chromosome inactivation patterns Fluorescence in situ hybridization
Unable to display preview. Download preview PDF.
- 4.Nowell PC. Chromosome abnormalities in myelodysplastic syndromes.Semin Oncol. 1992;19:189–194.Google Scholar
- 9.Kibbelarr RE, van Kamp H, Dreef EJ, et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes.Blood. 1992;79:1823–1828.Google Scholar
- 13.Jandl JH.Blood: Textbook of Haematology, 2nd ed. Boston, MA: Little, Brown; 1996.Google Scholar
- 14.Shinohara T, Takuwa N, Morishita K, et al. Chronic myelomono-cytic leukaemia with a chromosome abnormality (46,XY,20q-) in all dividing myeloid cells: evidence for clonal origin in a multipotent stem cell common to granulocyte, monocyte, erythrocyte, and thrombocyte.Am J Hematol. 1983;15:289–293.CrossRefPubMedGoogle Scholar
- 17.Kroef MJ, Fibe WE, Mout R, et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions.Blood. 1993;18:1849–1854.Google Scholar
- 23.Saitoh K, Miura I, Takahashi N, Miura AB. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes.Blood. 1998;92:2886–2892.PubMedGoogle Scholar
- 24.Parlier V, Tiainen M, Beris P, Miescher PA, Knuutila S, Jotterand-Bellomo M. Trisomy 8 detection in granulomonocytic, erythrocytic and megakaryocytic lineages by chromosomal in situ suppression hybridization in a case of refractory anaemia with ringed siderob-lasts complicating the course of paroxysmal nocturnal haemoglo-binuria.Br J Haematol. 1992;81:296–304.CrossRefPubMedGoogle Scholar
- 32.Van Kamp H, Fibbe WE, Jansen RP, et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene.Blood. 1992;80:1774–1780.PubMedGoogle Scholar
- 40.Miura I, Kobayashi Y, Takahashi N, Saitoh K, Muira AB. Short report: involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting.Br J Haematol. 2000;110:876–879.CrossRefPubMedGoogle Scholar
- 41.Takahashi N, Miura I, Saitoh K, Miura AB. Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization.Blood. 1998;92:4758–4763.PubMedGoogle Scholar
- 44.Busque L, Kohler S, De Hart D, et al. High incidence of polyclonal granulocytopoiesis in myelodysplastic syndromes (MDS) [abstract].Blood. 1993;82(suppl 1):196a.Google Scholar